mass spectrometric immunoassay | GenomeWeb

mass spectrometric immunoassay

After years of technical setbacks and challenges, mass spec-based clinical proteomics is "ready for prime time," a Thermo Fisher Scientific researcher told ProteoMonitor this week.

Thermo Fisher Scientific last week announced a collaboration with German diagnostics firm Immundiagnostik for development of mass spec-based assays for protein and peptide quantitation.

Thermo Fisher Scientific said this week that it has acquired protein biomarker firm Intrinsic Bioprobes, adding to its clinical proteomics portfolio.

The findings suggest that guidelines for chronic kidney disease testing, which have come under increased scrutiny in recent years, could benefit from including albumin and cystatin C levels in definitions of the disease.

New Products

Premium

Intrinsic Bioprobes, GE Healthcare

According to the patent, the company identified the proteins serum amyloid A and S-sulfonated transthyretin as biomarkers for myocardial infarction and developed a three-marker panel consisting of SAA, SS-TTR, and known MI biomarker myoglobin.

The collaboration aims to turn IBI's mass-spec immunoassay technology from a tool it has offered exclusively on a contract-research basis into a turnkey product available to clinical research laboratories around the world.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.